Advertisement
Advertisement
U.S. markets open in 6 hours 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.17+1.58 (+23.98%)
At close: 04:00PM EDT
8.25 +0.08 (+0.98%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close6.59
Open6.79
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range6.79 - 9.04
52 Week Range3.14 - 9.53
Volume12,933,010
Avg. Volume722,290
Market Cap806.463M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMVT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immunovant, Inc.
    Daily – Vickers Top Buyers & Sellers for 09/30/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

    NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L.P., Commodore Capital,

  • GlobeNewswire

    Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

    In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023. Previously announced programs for lead asset batoclimab continue at full speed. Two asset anti-FcRn franchise offers multiple potential development and commercial synergies, with composition of matter patent protection expected for IMVT-1402 through at lea

  • GlobeNewswire

    Immunovant to Present at Roivant Investor Day on September 28th

    NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28th, 2022. Roivant Investor Day presentation details: Date: Wednesday, September 28th, 2022 Time: 11:15 am Eastern Time Webcast: The presentation will be

Advertisement
Advertisement